Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Etripamil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Milestone's Long Regulatory Road Ends In Approval For Cardamyst
    Milestone's Long Regulatory Road Ends In Approval For Cardamyst

    15 Dec 2025

    // BIOSPACE

    https://www.biospace.com/fda/milestones-long-regulatory-road-ends-in-approval-for-cardamyst

    BIOSPACE
    15 Dec 2025
    Share Share
    Milestone Pharma ,’s Cardamyst Receives Approval in US
    Milestone Pharma ,’s Cardamyst Receives Approval in US

    12 Dec 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218571

    FDA
    12 Dec 2025
    Share Share
    Milestone Gets FDA Nod For CARDAMYST Nasal Spray In PSVT
    Milestone Gets FDA Nod For CARDAMYST Nasal Spray In PSVT

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/13/3204944/0/en/Milestone-Receives-FDA-Approval-of-CARDAMYST-etripamil-as-First-and-Only-Self-Administered-Nasal-Spray-for-Adults-with-Paroxysmal-Supraventricular-Tachycardia-PSVT.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Milestone Pharma To Unveil Etripamil Nasal Spray Analysis
    Milestone Pharma To Unveil Etripamil Nasal Spray Analysis

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179176/0/en/Milestone-Pharmaceuticals-to-Present-New-Analysis-from-Investigational-Etripamil-Nasal-Spray-Clinical-Trials-for-PSVT-at-the-American-Heart-Association-Scientific-Sessions-2025.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Milestone Pharma To Showcase Etripamil Data At AHA 2025
    Milestone Pharma To Showcase Etripamil Data At AHA 2025

    09 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/09/3164056/0/en/Milestone-Pharmaceuticals-to-Present-Data-on-Etripamil-at-the-American-Heart-Association-Scientific-Sessions-2025.html

    GLOBENEWSWIRE
    09 Oct 2025
    Share Share
    Milestone Pharma's Response to CARDAMYST CRL Accepted by FDA
    Milestone Pharma's Response to CARDAMYST CRL Accepted by FDA

    11 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/11/3113902/0/en/Milestone-Pharmaceuticals-Announces-FDA-Acceptance-of-the-Company-s-Response-to-the-CRL-for-CARDAMYST-etripamil-Nasal-Spray.html

    GLOBENEWSWIRE
    11 Jul 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.